Stockreport

Mesoblast and JCR Pharmaceuticals Expand Japan License Agreement to Use of Mesenchymal Stem Cells in Newborns With Insufficient Blood Flow to the Brain

Mesoblast Limited - American Depositary Shares  (MESO) 
US:NASDAQ Investor Relations: investorsmedia.mesoblast.com
PDF NEW YORK and MELBOURNE, Australia, June 11, 2019 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced it has expanded its partnership with JCR [Read more]